Key points from article :
Previously shown that Basis safely and sustainably increases NAD+ levels by an average of 40%.
Elysium’s NAD+ baseline study is ongoing.
Elysium recently shared the results of two studies for Basis.
1. acute kidney injury (AKI) Phase I dose-escalating safety study conducted at Massachusetts General Hospital
Gained its first Investigational New Drug (IND) application from the FDA late last year.
Made possible by Elysium’s open-access research model
2. 90-day toxicity study
Demonstrates the superior safety of Elysium’s proprietary nicotinamide riboside (NR-E)
Nicotinamide riboside is a precursor to NAD+ and classifies as GRAS (generally recognized as safe).
